In Brazil, several recurring mutations in BRCA1 and BRCA2 and a TP53 mutation (R337H) have been reported in high risk breast cancer cases.
We hypothesized that these recurring mutations may also be detected in the general
population and ovarian cancer cases in the state of Minas Gerais. To test this notion,
participants were recruited from the outpatient and the Gynecological clinic in the
UFMG Medical Center in Belo Horizonte, Minas Gerais, Brazil. BRCA1 (c.68_69delAG, c.5266dupC, c.181T>G, c.4034delA, c.5123C>A), BRCA2 (c.5946delT, c.8537_8538delAG, 4936_4939delGAAA), the c.156_157insAlu* BRCA2 and
the c.1010G>A *TP53 mutation were genotyped using validated techniques. Overall, 513
cancer free participants (273 men) (mean age 47.7 ± 15.1 years) and 103 ovarian cancer
cases (mean age at diagnosis 58.7 ± 9.6 years) were studied. None of the participants
were found to carry any of the genotyped mutations. We conclude that the recurring
mutations in BRCA1, BRCA2 and TP53 cannot be detected in the general population or consecutive ovarian cancer cases
in this geographical region in Brazil.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cancer GeneticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Genetic susceptibility to breast cancer.Mol Oncol. 2010; 4: 174-191https://doi.org/10.1016/j.molonc.2010.04.011
- Li-Fraumeni syndrome: cancer risk assessment and clinical management.Nat Rev Clin Oncol. 2014; 11: 260-271https://doi.org/10.1038/nrclinonc.2014.41
- Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.Am J Obstet Gynecol. 2015; 213: 161-165https://doi.org/10.1016/j.ajog.2015.03.003
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.Nat Genet. 1996; 14: 185-187
- BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.Am J Hum Genet. 2000; 66: 1259-1272
- Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.Genet Mol Biol. 2014; 37: 234-240
- Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype.Fam Cancer. 2012; 11: 657-660https://doi.org/10.1007/s10689-012-9551-5
- Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.J Natl Cancer Inst. 2014; 107: 379-393https://doi.org/10.1093/jnci/dju379
Article info
Publication history
Published online: November 16, 2015
Accepted:
November 9,
2015
Received in revised form:
November 4,
2015
Received:
September 22,
2015
Identification
Copyright
© 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Commentary regarding Schayek et al., entitled “The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil”Cancer GeneticsVol. 209Issue 6
- PreviewRecently, Schayek et al. (1) published a short communication about selected mutations in BRCA1, BRCA2 and TP53 in ovarian cancer (OC) cases and in a group of cancer-unaffected patients visiting a single health care center in the state of Minas Gerais (MG), Brazil. The authors did not find any of the mutations studied among 513 individuals evaluated and they concluded that “the recurring mutations in BRCA1, BRCA2 and TP53 cannot be detected in the general population or consecutive OC cases in this geographical region in Brazil”.
- Full-Text
- Preview
